Patents by Inventor Stephen J. Stahl

Stephen J. Stahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENERATION AND USE OF FAB, SCFV, AND RELATED BINDING MOLECULES SPECIFIC FOR HIV-1 REV
    Publication number: 20120201811
    Abstract: Described herein is the identification, though phage display, of a chimeric rabbit/human anti-Rev Fab (SJS-R1) that readily solubilized polymeric HIV-1 Rev. The Fab binds with very high affinity to a conformational epitope in the N-terminal half of HIV-1 Rev. The corresponding single chain antibody (scFv) was also prepared and characterized. Methods of making and using SJS-R1 Fab and SJS-R1 scFv, and antibodies and antibody fragments that share at least one CDR with SJS-R1 Fab, are provided. Specific described methods include methods of preventing or reversing polymerization of HIV Rev, methods of preventing or inhibiting replication of a lentivirus in a cell, methods of reducing infectivity of replication of a lentivirus, inhibiting Rev function in a cell infected with a lentivirus, and methods of treating a disease or symptom associated with Rev expression in an animal.
    Type: Application
    Filed: February 3, 2012
    Publication date: August 9, 2012
    Inventors: Stephen J. Stahl, Norman R. Watts, Paul T. Wingfield, Christoph Rader, Alasdair C. Steven
  • Truncated hepatocyte growth factor variant protein HGF/NK2
    Patent number: 7605127
    Abstract: The present invention relates to a novel truncated form of heptocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial HGF agonist. In particular, the present invention relates to the purification, molecular cloning, recombinant expression of the truncated HGF variants and related pharmaceutical compositions. The present invention further relates to the utilization of the small HGF variants to either inhibit HGF mitogenesis or stimulate HGF mitogenesis in cells expressing the receptor for HGF.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: October 20, 2009
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Andrew M. L. Chan, Jeffrey S. Rubin, Donald P. Bottaro, Stuart A. Aaronson, Stephen J. Stahl, Paul T. Wingfield, Vittoria Cioce
  • Truncated hepatocyte growth factor variants
    Publication number: 20030124671
    Abstract: The present invention relates to a novel truncated forms of hepatocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial HGF agonist. In particular, the present invention relates to the purification, molecular cloning, recombinant expression of the truncated HGF variants and related pharmaceutical compositions.
    Type: Application
    Filed: October 30, 2002
    Publication date: July 3, 2003
    Inventors: Andrew M.L. Chan, Jeffrey S. Rubin, Donald P. Bottaro, Stuart A. Aaronson, Stephen J. Stahl, Paul T. Wingfield, Vittoria Cioce